Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
Avalyn Pharma has raised $100.0M in total funding. The most recent round was Series D. The last funding was announced in July 2025.
Avalyn Pharma's investors include Norwest Venture Partners, Wellington Management, Catalio Capital Management, Novo Holdings, Perceptive Advisors.
Avalyn Pharma is headquartered in Seattle, United States.
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
Avalyn Pharma is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avalyn Pharma — Funding & Investors." VCBacked, July 22, 2025, https://www.vcbacked.co/company/avalyn-pharma. Accessed October 21, 2026.
VCBacked. (2025). Avalyn Pharma — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/avalyn-pharma
{{cite web |title=Avalyn Pharma — Funding & Investors |url=https://www.vcbacked.co/company/avalyn-pharma |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated